Results 21 to 30 of about 78,184 (307)

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

Blood, 2023
Introduction: BTK inhibitors (BTKis) are approved for chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL).
J. Seymour, C. Cheah, Ricardo D. Parrondo, Meghan C. Thompson, Don A. Stevens, M. Lasica, Michael L. Wang, Abhijeet Kumar, J. Trotman, M. Alwan, W. Ding, Kunthel By, B. Tariq, Xiangmei Chen, S. Fabre, J. Paik, Amit Agarwal, Constantine S. Tam   +17 more
semanticscholar   +1 more source

Stretched exponential relaxation in the mode-coupling theory for the Kardar-Parisi-Zhang equation [PDF]

, 2000
We study the mode-coupling theory for the Kardar-Parisi-Zhang equation in the strong-coupling regime, focusing on the long time properties. By a saddle point analysis of the mode-coupling equations, we derive exact results for the correlation function in
Cesnik C. E. S., Cesnik C.E.S., Lockyer A. J., Mukhopadhyay V., Peters D. A., Su W., Su W., Tilmann C.P., VanShoor M.C., Wakayama S.   +9 more
core   +5 more sources

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK

eLife, 2020
Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase active site.
Raji E Joseph, Neha Amatya, D Bruce Fulton, John R Engen, Thomas E Wales, Amy Andreotti   +5 more
doaj   +1 more source

Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. [PDF]

, 2014
Btk and Etk/BMX are Tec-family non-receptor tyrosine kinases. Btk has previously been reported to be expressed primarily in B cells and has an important role in immune responses and B-cell malignancies.
Bhardwaj, G, Changou, C, Chintapalli, S, Evans, CP, Guo, W, Kumaresan, P, Kung, H-J, Lam, KS, Liu, R, Ma, A-H, Mazloom, A, Patterson, R, Sanchez, E, Xiao, K, Xiao, W, Yang, JC, Yeh, C-T   +16 more
core   +2 more sources

BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

Journal of Hematology & Oncology, 2022
Bruton’s tyrosine kinase (BTK) is an essential component of multiple signaling pathways that regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising therapeutic target for various B cell malignancies and ...
Aqu Alu, H. Lei, Xuejiao Han, Yuquan Wei, Xiawei Wei   +4 more
semanticscholar   +1 more source

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani, Alam, Ashino, Baba, Bendall, Billottet, Burger, Burger, Byrd, Chang, Cordle, Dasmahapatra, David J. MacEwan, de Weers, Dos Santos, Doyle, Fiedler, Gallay, Grandage, Gu, Guzman, Hahn, Herman, Herrmann, Honda, Honigberg, Horwood, Ishii, Juliusson, Kawakami, Kim, Kojima, Kristian M. Bowles, Kvinlaug, Lyubov Zaitseva, Megan Y. Murray, Min, Mohamed, Nanri, Park, Quek, Renneville, Rushworth, Rushworth, Rushworth, Shinners, Sivina, Spiekermann, Stuart A. Rushworth, Sujobert, Tai, Tamburini, Tomasson, Tsukada, Vellenga, Venkataraman, Vetrie, Welch, Westermann, Zaitseva   +59 more
core   +1 more source

Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities

Cancers, 2023
Simple Summary Chronic lymphocytic leukemia (CLL) treatment scenario is rapidly evolving. As a consequence of longer observation, despite remarkable clinical results, treatment with ibrutinib is associated with long-term toxicities and resistance.
A. Frustaci, M. Deodato, G. Zamprogna, R. Cairoli, M. Montillo, A. Tedeschi   +5 more
semanticscholar   +1 more source

Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies

Journal of Hematology & Oncology, 2021
B cell receptor (BCR) signaling is involved in the pathogenesis of B cell malignancies. Activation of BCR signaling promotes the survival and proliferation of malignant B cells.
Danling Gu, Hanning Tang, Jiazhu Wu, Jianyong Li, Yi Miao   +4 more
doaj   +1 more source

Kvantitatív drámaelemzés és az idő

Digitális Bölcsészet, 2023
A kvantitatív drámaelemzés legtöbbször a színművek egészére vonatkozó, statikus mérőszámokból indul ki, továbbá kevés figyelmet fordít az e mérőszámokkal leírt szerkezeti tulajdonságok történeti változásaira. A tanulmányban ezért korábbi eredményeinket,
Botond Szemes, Magyar Magyar
doaj   +1 more source

Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA). [PDF]

, 1994
The gene responsible for X-linked agammaglobulinemia (XLA) has been recently identified to code for a cytoplasmic tyrosine kinase (Bruton's agammaglobulinemia tyrosine kinase, BTK), required for normal B cell development. BTK, like many other cytoplasmic
Chen, SH, Hagemann, T, Kwan, SP, Nilsson, L, Ochs, HD, Rawlings, DJ, Saffran, DC, Smith, CI, Vihinen, M, Witte, ON, Zhang, M, Zhu, Q   +11 more
core   +1 more source